FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896849737> ?p ?o ?g. }

• W2896849737 endingPage "6870" @default.
• W2896849737 startingPage "6863" @default.
• W2896849737 abstract "Relapsed and refractory acute myeloid leukemia (RR-AML) still poses major treatment concerns. Current treatments include high doses of cytarabine or fludarabine in combination with cytarabine and G-CSF (FLAG), but provide mixed results. Low-dose decitabine, a hypomethylating drug, in combination with aclarubicin and cytarabine (DAC) has shown safety and efficacy in the treatment of AML; however, clinical data are limited for the treatment of RR-AML.In this study, we retrospectively compared the response and safety of DAC vs FLAG for RR-AML patients.For the 35 patients with RR-AML enrolled in this study, the overall response rates reached 100% and 55.6% in the DAC group and FLAG group, respectively (P=0.002). Complete response rates after DAC and FLAG treatment were 64.7% and 33.3%, respectively (P=0.002). Median overall survival (95% CI) of the DAC treatment group was significantly higher than for the FLAG group (median not achieved vs 16.8 months, P=0.021).DAC treatment was also more effective in those patients with poor prognosis, suggesting that DAC resulted in a better outcome for RR-AML treatment. In conclusion, in our study, DAC therapy provided more safety and effectiveness and lower toxicity in the treatment of RR-AML compared to FLAG therapy." @default.
• W2896849737 created "2018-10-26" @default.
• W2896849737 creator A5001650535 @default.
• W2896849737 creator A5006967614 @default.
• W2896849737 creator A5019573704 @default.
• W2896849737 creator A5039467825 @default.
• W2896849737 creator A5044756293 @default.
• W2896849737 creator A5046068820 @default.
• W2896849737 creator A5051407359 @default.
• W2896849737 creator A5056436243 @default.
• W2896849737 creator A5083700605 @default.
• W2896849737 creator A5085352453 @default.
• W2896849737 creator A5091032181 @default.
• W2896849737 date "2018-10-01" @default.
• W2896849737 modified "2023-09-22" @default.
• W2896849737 title "Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations" @default.
• W2896849737 cites W1606162789 @default.
• W2896849737 cites W1982035148 @default.
• W2896849737 cites W1983956179 @default.
• W2896849737 cites W1998476920 @default.
• W2896849737 cites W2038736055 @default.
• W2896849737 cites W2046922854 @default.
• W2896849737 cites W2048636850 @default.
• W2896849737 cites W2056080464 @default.
• W2896849737 cites W2056968638 @default.
• W2896849737 cites W2070044750 @default.
• W2896849737 cites W2079025304 @default.
• W2896849737 cites W2081279521 @default.
• W2896849737 cites W2083694389 @default.
• W2896849737 cites W2086492419 @default.
• W2896849737 cites W2101892777 @default.
• W2896849737 cites W2106084333 @default.
• W2896849737 cites W2122782605 @default.
• W2896849737 cites W2127281738 @default.
• W2896849737 cites W2141869972 @default.
• W2896849737 cites W2159163046 @default.
• W2896849737 cites W2159507916 @default.
• W2896849737 cites W2166628031 @default.
• W2896849737 cites W2409251897 @default.
• W2896849737 cites W2444391736 @default.
• W2896849737 cites W2509971058 @default.
• W2896849737 cites W2512938559 @default.
• W2896849737 cites W2556473631 @default.
• W2896849737 cites W4252998175 @default.
• W2896849737 doi "https://doi.org/10.2147/ott.s161919" @default.
• W2896849737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6190628" @default.
• W2896849737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349319" @default.
• W2896849737 hasPublicationYear "2018" @default.
• W2896849737 type Work @default.
• W2896849737 sameAs 2896849737 @default.
• W2896849737 citedByCount "7" @default.
• W2896849737 countsByYear W28968497372019 @default.
• W2896849737 countsByYear W28968497372020 @default.
• W2896849737 countsByYear W28968497372022 @default.
• W2896849737 countsByYear W28968497372023 @default.
• W2896849737 crossrefType "journal-article" @default.
• W2896849737 hasAuthorship W2896849737A5001650535 @default.
• W2896849737 hasAuthorship W2896849737A5006967614 @default.
• W2896849737 hasAuthorship W2896849737A5019573704 @default.
• W2896849737 hasAuthorship W2896849737A5039467825 @default.
• W2896849737 hasAuthorship W2896849737A5044756293 @default.
• W2896849737 hasAuthorship W2896849737A5046068820 @default.
• W2896849737 hasAuthorship W2896849737A5051407359 @default.
• W2896849737 hasAuthorship W2896849737A5056436243 @default.
• W2896849737 hasAuthorship W2896849737A5083700605 @default.
• W2896849737 hasAuthorship W2896849737A5085352453 @default.
• W2896849737 hasAuthorship W2896849737A5091032181 @default.
• W2896849737 hasBestOaLocation W28968497371 @default.
• W2896849737 hasConcept C104317684 @default.
• W2896849737 hasConcept C121332964 @default.
• W2896849737 hasConcept C126322002 @default.
• W2896849737 hasConcept C136119220 @default.
• W2896849737 hasConcept C142424586 @default.
• W2896849737 hasConcept C143998085 @default.
• W2896849737 hasConcept C150194340 @default.
• W2896849737 hasConcept C185592680 @default.
• W2896849737 hasConcept C190727270 @default.
• W2896849737 hasConcept C202444582 @default.
• W2896849737 hasConcept C2776012956 @default.
• W2896849737 hasConcept C2776694085 @default.
• W2896849737 hasConcept C2776730729 @default.
• W2896849737 hasConcept C2776755627 @default.
• W2896849737 hasConcept C2778041864 @default.
• W2896849737 hasConcept C2778461978 @default.
• W2896849737 hasConcept C2778729363 @default.
• W2896849737 hasConcept C2779263901 @default.
• W2896849737 hasConcept C2780235182 @default.
• W2896849737 hasConcept C2780847677 @default.
• W2896849737 hasConcept C33923547 @default.
• W2896849737 hasConcept C55493867 @default.
• W2896849737 hasConcept C71924100 @default.
• W2896849737 hasConcept C87355193 @default.
• W2896849737 hasConcept C90924648 @default.
• W2896849737 hasConceptScore W2896849737C104317684 @default.
• W2896849737 hasConceptScore W2896849737C121332964 @default.
• W2896849737 hasConceptScore W2896849737C126322002 @default.
• W2896849737 hasConceptScore W2896849737C136119220 @default.
• W2896849737 hasConceptScore W2896849737C142424586 @default.

• next